Introduction
Methylthioadenosine phosphorylase (MTAP) deficiency in tumor can be therapeutically exploited for selective therapy. [1] [2] [3] MTAP, the housekeeping enzyme, plays a major role in the salvage of both adenine and methionine with 5Ј-deoxy-5Ј-methylthioadenosine (MTA) as substrate. 4, 5 This salvage pathway is the major source of adenine in human cells. 6 While MTAP deficiency has been demonstrated in many tumor cell lines and primary tumors such as leukemias, melanomas, brain tumors and non-small cell lung cancers, [7] [8] [9] [10] [11] all normal cells including erythrocytes and hematopoietic stem/ progenitor cells contain the enzyme in abundance. 12, 13 We and others have shown that MTAP deficiency in cancer offers a specific molecular target for selective therapy in in vitro studies. 2, [14] [15] [16] Cells deficient in MTAP are unable to utilize MTA, the natural enzyme substrate, or a substitute such as 5Ј-deoxyadenosine to synthesize methionine and/or adenine nucleotides. 1, 7 By combining with MTA or 5Ј-deoxyadenosine to rescue normal cells, bacterial L-methioninase or purine de novo synthesis inhibitor L-alanosine can selectively kill MTAP deficient tumor cells in vitro. 2, 3, 14 Recently it was reported that MTAP deficient T cell acute lymphoblastic leukemia (T-ALL) cells were selectively killed with L-alanosine and that normal lymphocytes were rescued with 5Ј-deoxyadenosine. 1 The MTAP gene resides on chromosome 9p about 100 kb telomeric to the tumor suppressor genes p16 and p15 which encode negative regulators of the cell cycle. [17] [18] [19] The deletion of p16 has been demonstrated in many cancers and associated with carcinogenesis as well as disease progression in some cancers. [20] [21] [22] [23] The MTAP gene is frequently co-deleted with the p16 gene in adult T cell leukemia (ATL) and childhood T-ALL. 3, 24 ATL, clinically a heterogeneous disease, responds poorly to therapy. 25 The deletion of p16 gene predicts the shortened survival in ATL and plays a key role in the progression of the disease from chronic to acute form. 26, 27 Although no such relationship existed at diagnosis, p16 deletion was associated with the shorter survival in patients with relapsed T-ALL. 28 Since chromosome 9p deletions in ATL and T-ALL predict prognosis, a precise and accurate diagnostic method for detection of such gene deletions is needed. We and other investigators have previously reported the use of various methods to determine the gene status at chromosome 9p, including MTAP enzyme assay, Western blot analysis, fluorescence in situ hybridization (FISH), end-point quantitative PCR and Southern blot analysis. 2, 3, 10, 29 The accurate diagnosis of chromosome 9p deletions has been hampered by the presence of contaminating normal cells in primary samples. In search of a sensitive and accurate method, we have developed a real-time quantitative PCR (RQ-PCR) assay based on the TaqMan chemistry (Perkin Elmer-Applied Biosystems ABI Prism 7700 sequence detection system) to evaluate MTAP and p16 gene status in samples from patients with ATL and T-ALL. This method for nucleic acid quantification is fully automated, rapid and sensitive and eliminates the need for post-PCR processing, a potential source of carryover contamination.
Moreover, the method has a high sample throughput, since 96 reactions can be analyzed in 2 h. 30, 31 The primary samples from 29 ATL patients were analyzed by the newly developed RQ-PCR assay, that had been studied for the chromosome 9p deletions by Southern blot analysis in our previous report. 24 We then analyzed 39 primary T-ALL samples to validate the assay. The results in the present study indicate that the RQ-PCR assay developed is a sensitive and accurate method for detecting homozygous deletions of MTAP and p16 genes even in samples containing as low as 33% blast cells.
Materials and methods

Patient samples
DNA from peripheral blood mononuclear cells of 29 ATL patients (20 acute type and nine chronic type) was examined. Thirty-four of the 39 T-ALL samples were derived from either peripheral blood or bone marrow of patients enrolled in the Pediatric Oncology Group (POG Study No. 9000 and No. 9400). 3 The remaining five (patient Nos 35-39) were from patients diagnosed as T-ALL at Mie University Hospital. The blast cell content ranged from 17% to 93% in ATL samples and from 66% to 100% in T-ALL, with data unavailable for eight T-ALL samples. DNA samples from peripheral mononuclear cells of 10 healthy donors were used as control. Criteria for diagnosis and sample handling were as previously reported. 3, 24 Peripheral and bone marrow blood samples were obtained from patients after obtaining informed consent with the approval of the institutional ethical committee.
Tumor cell lines
The cell lines used were SO4, ST-1 and KK-1, all determined to be of ATL origin as previously reported. 24 DNA from the breast cancer cell MCF-7 bearing homozygous deletion of both MTAP and p16 genes was used as negative control.
Theoretical basis of RQ-PCR
What is critical in RQ-PCR is the threshold cycle (Ct), defined as the fractional cycle number at which the fluorescence generated by cleavage of the probe passes a fixed threshold above baseline. The fluorescence is due to hydrolysis of the duallabeled fluorogenic hybridization probe by 5Ј-3Ј nuclease Table 1 Oligonucleotides used for RQ-PCR amplification of MTAP and p16 genes Gene Sequences of primes and probes
activity of DNA polymerase. Thus, instead of the amount of PCR product accumulated after a fixed number of cycles, the Ct value is determined during the log phase of PCR product accumulation and is used for quantification. The higher the initial amount of the target DNA, the earlier an increase in the fluorescence is detected. The target gene copy number in samples is quantified by measuring the Ct value. Thus in tumors with a homozygously deleted target gene the Ct value will depend on the proportion of contaminating normal cells present. Since the precise amount and the quality of genomic DNA used in each reaction are unknown, the MTAP pseudogene (X4) on chromosome 3q28 32 The normalized Ct is expected to give a value of 1 in tumor samples without deletion, as opposed to 0 in samples bearing the homozygous gene deletion without normal cell contamination (100% blast cell content). Therefore, normalized Ct values between 0 and 1 are expected in primary tumor samples containing tumor tissues with homozygously deleted target genes and varying amounts of normal tissues.
Primers and probes
The primers and fluorogenic probes used are shown in Table  1 . The primers were designed to amplify MTAP exon 8 and p16 exon 2. 17, 19, 32 The probes were synthesized by PEApplied Biosystems with the reporter dye FAM at the 5Ј end and the quencher dye TAMRA at the 3Ј end.
RQ-PCR assay
To determine the sensitivity of RQ-PCR, plasmid DNA containing MTAP exon 8 was serially diluted to obtain the copy number ranging from 10 1 to 10 7 , followed by the RQ-PCR (Figure 1 ). The PCR reactions were carried out in a total volume of 50 l TaqMan PCR buffer (TaqMan PCR core reagent kit; PE Biosystems, Foster City, CA, USA) containing 30-400 ng DNA, 400 nm of each primer and 200 nm of TaqMan probe. The thermal cycling condition consisted of an initial denaturation at 90°C for 10 min, followed by 50 cycles of the denaturation at 95°C for 15 s and the simultaneous annealing and extension at 60°C for 1 min. All reactions were performed The dilution test to determine the sensitivity of real-time PCR. PCR was done using serially diluted samples of plasmid DNA containing MTAP exon 8 as described in the Materials and methods. Relative fluorescence was plotted against the number of cycles. The reaction containing no template DNA (NT) was used as a negative control.
Figure 2
Accuracy of RQ-PCR assay. To determine the accuracy of the assay, the mixture of DNA from normal healthy donor and from MCF-7 cells deleting both MTAP and p16 genes at various ratios was used for RQ-PCR as described in the Materials and methods. The Ct values obtained for MTAP and X4 genes were plotted against the relative ratio of normal DNA in the mixture.
in the ABI Prism 7700 Sequence detection System (PerkinElmer Applied Biosystems), which detects the signal from the fluorogenic probe during PCR and gives the Ct values automatically. For each test sample, PCR was run in duplicate.
After ascertaining sensitivity, the accuracy of the assay was determined with the mixture of DNA from normal lymphocytes of healthy donors and from MCF-7 cell line homozygously deleting MTAP and p16 genes at various ratios (Normal:MCF-7 = 100:0, 80:20, 60:40, 40:60, 20:80). RQ-PCR for MTAP and X4 on DNA mixtures were performed in parallel and the resulting Ct values were plotted against the relative ratio of normal DNA in the mixture (Figure 2 ).
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Results
Sensitivity of RQ-PCR assay
The dilution test was performed to determine the sensitivity of the assay using serially diluted samples of plasmid DNA containing MTAP exon 8. As shown in Figure 1 , PCR was able to amplify the target MTAP exon 8 from samples containing 10 1 to 10 7 copies. The dynamic range was wide enough for clinical application of the assay. When the Ct value was plotted against the copy number, the linear correlation was obtained with correlation coefficient (r 2 ) of 0.995 (data not shown).
Accuracy of RQ-PCR assay
Since the primary samples were inevitably contaminated with the normal cell component, it has been difficult to accurately diagnose the homozygous gene deletions in primary samples. As described in the Materials and methods section, we analyzed MTAP exon 8 and X4 gene in the mixture of DNA from normal cells and from MCF-7 homozygously deleting p16 and MTAP genes at the various ratios to see if the assay is able to quantify the gene dosage in the samples relevant to the pri- 
Feasibility of the assay: MTAP and p16 gene status in ATL
To see whether or not this assay is applicable to the primary samples containing both normal cells and cancer cells, 29 primary ATL samples were analyzed. The results of MTAP and p16 gene status are shown in Table 2 , along with the clinical characteristics. The ATL samples had a blast cell content ranging from 17% to 93%. The normalized Ct MTAP and Ct p16 values for each patient are shown in Figure 3 , with respect to the blast cell content in the samples. Six (20.7%) of 29 samples homozygously deleted the MTAP gene, while eight (27.6%) of 29 had the homozygous deletion of the p16 gene. As reported previously, all six samples deleting the MTAP gene were found to have p16 deletion as well. 24 Two samples deleted the p16 gene alone. Since ATL samples including these 29 samples had previously been analyzed by Southern blot analysis, 24 we compared RQ-PCR assay with Southern blot analysis. As shown in Table 2 , homozygous deletions of MTAP and p16 were detected in three (10.3%) and five (17.2%), respectively, of the same 29 samples by Southern blot analysis. As mentioned above, however, RQ-PCR assay detected homozygous deletions of both MTAP and p16 in three more samples that were from two chronic type and one acute type ATL patients with blast cell content of 44%, 50% and 33% (Patient Nos 2, 28 and 22, respectively, in Table 2 ). The minimum blast cell content in the sample where Southern blot analysis detected homozygous deletion of either MTAP or p16 was 60% in contrast to 33% with RQ-PCR. The overall concordance of these assays was 89.7% (26 of 29 cases) for both MTAP and p16 (deleted and undeleted).
MTAP and p16 gene status in T-ALL
MTAP and p16 genes in T-ALL samples were analyzed by RQ-PCR assay. As shown in Table 3 , homozygous deletions of MTAP and p16 genes were detected in 15 (38.5%) and 23 (59%), respectively, of the 39 T-ALL samples. The blast cell content of these samples ranged from 66% to 100% with data unavailable for eight patients. As observed in ATL samples (Table 2 ), all 15 samples deleting the MTAP gene also deleted the p16 gene. Eight samples deleted the p16 gene alone.
Discussion
The advent of real-time quantitative fluorescence PCR, a technique that allows rapid analysis of multiple samples without any post-PCR sample processing, fosters great potential for useful diagnostic and monitoring tests in the clinical setting.
30
Utilizing RQ-PCR we developed an assay to accurately determine MTAP and p16 homozygous gene deletions in primary samples from ATL and childhood T-ALL.
Other methods such as Southern blot analysis, end-point quantitative PCR, and FISH have been used to assess MTAP and p16 gene status in cancer cells. The high tumor to normal cell ratio required for accurate diagnosis of gene deletions by Southern blot analysis poses a major limitation on its application. 33 This is exemplified in the study by Okuda et al, 23 in which Southern blot analysis could not be performed on ALL samples with blast cell content of less than 70%. Our results also support their finding in that Southern blot analysis could not detect homozygous deletions in samples with blast cell content less than 60% (Table 2) . End-point quantitative PCR is also frequently used for analysis of chromosome 9p deletions. As with Southern blot analysis, normal cell contamination made it difficult to detect homozygous deletions in primary samples. 29 Moreover, laborious post-PCR handling is required. Although FISH allows visualization of signals within individual nuclei and thus discrimination between blast and normal cells, a high level of expertise is required for its application. In addition, small deletions detected by PCR were missed by FISH as Perry et al 29 reported. To see if the newly developed RQ-PCR assay can overcome the above-mentioned problems with other methods, we evaluated 29 primary ATL samples whose blast cell content ranged from 17% to 93%. Out of 29 samples, six and eight were found to homozygously delete MTAP and p16 genes, respectively. It is of note that homozygous gene deletions were detected in three samples with blast cell content of 33%, 44% and 50% by RQ-PCR assay, although not detected by Southern blot analysis.
We then applied this assay to 39 primary T-ALL samples. Table 2 .
The incidences of homozygous deletions of MTAP and p16 genes were 38.5% and 59%, respectively, in T-ALL in the present study, which are in agreement with previous reports. 3, 28, 34 It is also consistent with our previous findings that MTAP gene was co-deleted with p16 gene. 3, 24 The present results have shown that RQ-PCR was able to detect homozygous deletions of MTAP and p16 genes in such primary samples as acute type ATL with blast cell content of 33%.
In conclusion, the RQ-PCR assay we have developed was more sensitive, quantitative and rapid than other methods such as Southern blot analysis, end-point quantitative PCR and FISH. Therefore, this assay would be useful in searching for candidates for selective therapy targeting MTAP deficiency in malignancies including ATL and T-ALL. 
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